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Active specific immunotherapy
in the management of
adenocarcinoma of the pancreas
BR YACYSHYN MD FRCPC, BM LONGENECKER PHD, WA BIERMANN MD, D MCCLURE MD,
S POPPEMA PHD FRCPC, MB BOWEN-YACYSHYN PHD
IN 1984, SPRINGER DESCRIBED THEpresence of blood group precursor
antigens Tn and T on carcinomas (1).
Further studies have shown that Tn,
the monosaccharide precursor of TF,
and its siaylated form STn are ex-
pressed on 90% of adenocarcinomas,
and the amount of these epitopes ex-
pressed appears to be correlated with
carcinoma aggressiveness (1). Many
adenocarcinomas have been found to
secrete immunosuppressive mucins
which have these normally cryptic car-
bohydrates exposed. Fung et al (2)
have synthesized these carbohydrate
haptens and conjugated them to the
protein carrier keyhole limpet hema-
cyanin (KLH). These glycoconjugates
have been shown to be protective
against lethal tumour challenge in
mice (2). In 1989, human clinical trials
began using TF-KLH and STn-KLH (a
synthetic glycoconjugate consisting of
STn – a sialyated blood group precursor
– attached chemically to a KLH protein
backbone) with the hope of circum-
venting the immunosuppression in
adenocarcinoma patients and creating
a humoral and cellular antitumour re-
sponse (2).
We report the first case of active
specific immunotherapy (ASI) used as
primary therapy for adenocarcinoma of
the pancreas. This form of treatment
has been previously shown to have
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Active specific immunotherapy for pancreatic adenocarcinoma and subsequent
immunohistochemical analysis of tumour tissue have not been previously re-
ported. To date, the therapy of pancreatic adenocarcinoma has been largely un-
successful. A patient treated with a therapeutic ‘cancer vaccine’ and the
immunological impact on the primary tumour of this potential new therapy are
described. To the authors’ knowledge, this is both the first patient to be treated
with active specific immunotherapy for pancreatic adenocarcinoma and the first
to be studied immunologically by flow cytometry and immunohistochemistry
with an apparent positive clinical impact.
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Immunothérapie active spécifique pour le traitement de
l’adénocarcinome du pancréas
RÉSUMÉ : L’immunothérapie active spécifique dans les cas d’adénocarcinome
du pancréas et l’analyse immunohistochimique subséquente du tissu tumoral
n’ont encore jamais fait l’objet d’un rapport. À ce jour, le traitement de l’adéno-
carcinome pancréatique a souvent échoué. Un patient traité par un vaccin anti-
cancer thérapeutique et l’impact immunologique sur la tumeur primitive de ce
nouveau traitement expérimental sont décrits ici. À la connaissance de l’auteur,
il s’agit du premier patient à être traité par immunothérapie active spécifique
pour un adénocarcinome du pancréas et le premier à être étudié sur le plan immu-
nologique par flux-cytométrie et épreuves d’immunohistochimie avec des résul-
tats cliniques apparemment favorables.
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benefit in treatment of neoplasms in
several animal and human trials. A
tumour-associated carbohydrate anti-
gen sialyl-Tn (DAcNeu2-
6DGalNAc) was synthesized and at-
tached chemically to a KLH protein
carrier. This antigen was emulsified in
DETOX adjuvant (RIBI Immuno-
Chem Research, Inc, Montana) and
injected subcutaneously into a patient
after cyclophosphamide pretreatment.
After two courses of ASI, a Whipple’s
procedure was performed and the pri-
mary tumour obtained surgically was
analyzed by immunohistochemistry.
The patient survived 14 months from
diagnosis and suffered no adverse reac-
tions from the ASI injections, unlike
from chemotherapy or radiation.
CASE PRESENTATION
A 52-year-old woman was seen July
13, 1992, on referral from her family
physician after three weeks of progres-
sive jaundice. Symptoms compatible
with obstructive jaundice were elicited
on history with dark urine and pale
stool colour. A computed tomography
(CT) scan was performed (Figure 1)
which revealed a 4x4 cm mass involv-
ing the uncinate process of the pan-
creas with associated pancreatic,
common bile duct and intrahepatic
duct dilation. On July 28, the patient
underwent a Roux-en-Y choledochoje-
junostomy with needle aspiration of
the uncinate process of the pancreas.
Cytopathology confirmed adenocarci-
noma of the pancreas (Figure 2). The
patient consented to participate in a
study of ASI as the sole therapy for her
malignancy. The patient underwent
standard protocol pretreatment for ASI
with cyclophosphamide (300 mg/m2)
followed by two courses of ASI with
STn-KLH (100 g) plus adjuvant DE-
TOX B (RIBI) given October 2 and 16,
1992. Peripheral blood was obtained
for peripheral blood mononuclear cell
immunophenotyping by flow cytome-
try before ASI and three months after
the last injection. No adverse events
were noted by the patient.
Subsequently, in an effort to seek
more definitive therapy, the patient
sought an opinion from a second sur-
geon who consented to excise the pri-
mary tumour. CT scan and angiography
performed preoperatively October 21,
1992 confirmed no progression in tu-
mour size with persistence of a 4x4 cm
mass in the pancreatic head, and no
metastatic disease was found. A Whip-
ple’s procedure was performed Novem-
ber 2, 1992 and the patient underwent
an unremarkable postoperative recov-
ery. Frozen sectioning of the pancreatic
head confirmed the gross findings of an
ill-defined, 2.5 cm average diameter,
extremely firm indurated head of pan-
creas and no involved lymph nodes.
Fixed tumour tissue was studied in
detail by immunohistochemistry to
identify the nature of the immune
response initiated in the pancreas.
Unfortunately, a liver metastasis was
identified in February 1993 and fine
needle aspiration biopsy confirmed
metastatic pancreatic adenocarci-
noma. The patient submitted to addi-
tional palliative care and was mobile up
to one week before death in late Sep-
tember 1993 from metastatic pancre-
atic adenocarcinoma and inferior vena




Flow cytometry performed before
and after the patient’s course of ASI
vaccines revealed a stable CD4:CD8
ratio greater than 1, increased expres-
sion of CD25 on the CD4 subset after
immunization (indicating interleukin-
2 receptor was present on these ‘act-
ivated cells’), and stable B and NK
populations. Immunohistochemistry of
fixed and imbedded tumour was per-
formed using the Dakopatts ABC tech-
nique (Dako, California). A marked
paucity of tumour cells was noted in all
sections stained, with evidence of
chronic inflammation. An inflamma-
tory infiltrate was seen in several sec-
tions, and consisted mainly of CD8+ T
lymphocytes (Figure 3). Additional
staining confirmed an activated lym-
phocyte infiltrate by CD45RB (a lym-
phocyte CD45 transitional isoform,
not shown) and MT1 (CD43) on acti-
vated lymphocytes (Figure 4) (3).
Figure 1) Computed tomography scan of abdomen. A 4x4 cm mass is
identified involving the uncinate process with associated pancreatic, com-
mon bile duct and intrahepatic duct dilation
Figure 2) Cytopathology before active specific immunotherapy. Adeno-
carcinoma cells are consistent with the patient’s clinical presentation and
computed tomography scan
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DISCUSSION
ASI attempts to involve the recogni-
tion of specific T cells challenged by
synthetic glycoconjugates vaccinated
into a recipient afflicted by cancer to
incite an immune response against that
tumour. Of phase II trials underway for
a number of malignancies, we present
one such patient who, to date, is the
first patient to survive statistically be-
yond that expected by nonoperative
management alone (4). Survivals of 11
to 21 months for patients with pancre-
atic cancer treated with radiotherapy
and chemotherapy have been de-
scribed (5). No information about the
immune status of long term survivors
regarding the peripheral blood and tu-
mour lymphocyte composition that
may allow long term survival has been
identified (5). Our patient had periph-
eral blood lymphocyte analysis both
before and after therapy, as well as im-
munohistochemistry of the resected tu-
mour removed at Whipple’s procedure.
In this paper we describe prolonged
survival in a patient treated with two
courses of ASI and investigated with
immunohistochemistry of the primary
malignancy. The recent use of ASI in
carcinoma of the breast and ovary has
created interest in oncology due to the
minimal side effects with such treat-
ment (6,7). Our patient entered this
phase II study treatment protocol with
informed consent, and received
pretreatment with cyclophospha-
mide. Cyclophosphamide pretreat-
ment is thought to augment an im-
mune response in humans by depleting
suppressor T lymphocytes (8-10). Two
courses of vaccination treatment with
STn-KLH were administered subcuta-
neously with no adverse local or sys-
temic reactions (6). Immunohisto-
chemistry of the primary tumour after
surgical resection revealed a fibrotic,
scarred tumour with a paucity of malig-
nant cells. Although dense, peritumour
fibrosis has been described in cancer of
the pancreas, this contrasts with the
pretreatment aspiration needle biopsy
of the same area where cytology re-
vealed abundant tumour cells. The cel-
lular infiltrate found on immunohisto-
chemistry revealed positive
lymphocyte staining with CD8, CD43
and CD45RO. This supports an im-
mune response in the area of the pri-
mary neoplasm which may not be at-
tributable to ASI.
ASI has been considered and ad-
ministered in a number of animal
and human trials. The benefit of gener-
ating T cell-dependent immunoglobu-
lin G responses to carbohydrate
antigens conjugated to protein carriers
has been tested in other malignancies
(7). Pilot studies of ASI in ovarian can-
cer and metastatic breast cancer have
been promising (6,7). Moreover, toxic-
ity in these studies has been largely
minimal, consisting of local granulo-
mata at vaccine sites. To date, these
studies have shown some surprising
clinical outcomes in patients even with
preexisting metastatic disease. ASI plus
chemotherapy, or as in our case with
surgical resection, may improve or pro-
long disease-free survival. Such therapy
will be further assessed in adenocarci-
noma of the pancreas, a disease where
there has been obvious lack of clinical
progress.
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